March 28th 2024
A recent study revealed that digital composite measures for bradykinesia outperformed traditional assessment methods for Parkinson disease over a 12-month period.
FAQs in MS: Exploring Provocative Questions From MS Meeting Updates
View More
BURST CME™: Taking ALS Management to the Next Level
View More
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
High-Fidelity Manikin Training Program Addresses Pitfalls in Epilepsy Monitoring Unit Care
Following development and implementation of a simulation laboratory training session to all staff in the EMU, there were statistically significant improvements in orientation assessment, speech assessment, motor assessment, oxygen administration, and vital sign collection in the short-term reassessment.
FDA Approves Alexion's Ravulizumab-cwvz for Neuromyelitis Optica Spectrum Disorder
March 25th 2024The approval is supported by phase 3 data which showed ravulizumab-cwvz met its primary end point of time to first on-trial relapse, with no relapses observed in 58 patients with NMOSD over a median treatment duration of 73 weeks.
Lantheus Announces Collaboration With NIH to Study Tau Imaging Agent in Alzheimer Disease
The CLARiTI study spans across all 37 Alzheimer Disease Research Centers, collecting evidence on imaging and blood-based biomarkers to generate etiologic patient profiles of mixed dementia.
Unlocking New Treatment Insights for Children With Epileptic Spasms: The TOPAMAD Trial
TOPAMAD will include 70 children with epileptic spasms who experienced hormonal therapy failure to determine whether modified Atkins diet or topiramate is a more effective treatment approach.
Introducing Sleeping Around the Podcast × NeurologyLive
March 21st 2024Sleeping Around the Podcast is hosted by Anne Marie Morse, DO, FAASM, a neurologist with special qualifications in child neurology and a sleep medicine specialist, who has partnered with NeurologyLive to bring you bite-sized, sleep-focused content.
Interim Phase 2 Data Highlight IGC-AD1 as a Potential Therapy for Alzheimer Disease Agitation
Over a 6-week period, patients taking IGC-AD1, on average, experienced a more significant reduction in agitation scores compared with those on placebo, with effects seen as early as week 2.
The Glymphatic Pathway: Evaluating Neurological Conditions From a New Perspective
March 20th 2024This complex waste clearance pathway within the CNS plays a crucial role in maintaining brain homeostasis, as a mechanism of protein waste removal alongside autophagy and protein aggregate ubiquitination.
NeuroVoices: Aki Ko, on mRNA Therapeutics for Duchenne Muscular Dystrophy
The chief executive officer at Elixirgen Therapeutics provided commentary on the promise of the Bobcat mRNA, and the mechanism of action for mRNA-like therapies to treat Duchenne muscular dystrophy.